bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S7 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Effects of EGFR/RAF/MEK inhibitors on MAPK/ERK pathway in squamous cell carcinoma (SCC) cells.
Supplementary Figure S5 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Cisplatin-resistant H596 sustained activation of p-ERK after cisplatin treatment.
Supplemental Figure S4 from Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
Authors: Wang Xinning , Huang Steve S. , Heston Warren D.W. , Guo Hong , Wang Bing-Cheng , Basilion James P.
Published: April 2023

Supplemental Figure S4: Comparison of the quantification of PC3pip tumor uptake of PSMA-1-IR800 and PSMA-1-Cy5.5 as determined by FMT. The amount of PSMA-1-IR800 in PC3pip reached a maximum at 4 hours post injection, then dropped gradually. The amount of PSMA-1-Cy5.5 reached its peak at 24 hours post injection, then remained constant.
Supplemental Figure S3 from Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
Authors: Wang Xinning , Huang Steve S. , Heston Warren D.W. , Guo Hong , Wang Bing-Cheng , Basilion James P.
Published: April 2023

Supplemental Figure S3: (A) HPLC chromatography of PSMA-1-Cy5.5. PSMA-1-Cy5.5 has a retention time at 39.4 min. (B) MALDI-TOF mass spectrum of PSMA-1-Cy5.5, which shows M+1=1651.7.
Supplemental Figure S2 from Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
Authors: Wang Xinning , Huang Steve S. , Heston Warren D.W. , Guo Hong , Wang Bing-Cheng , Basilion James P.
Published: April 2023

Supplemental Figure S2: (A) HPLC chromatography of PSMA-1-IR800. PSMA-1-IR800 has a retention time at 23.4 min. (B) MALDI-TOF mass spectrum of PSMA-1-IR800, which shows M+1=2071.8.
Supplementary Figure S3 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Effects of cisplatin treatment on levels of phosphorylated kinases are assessed in H596 and Calu-1 cells.
Supplemental Figure 1 from Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
Authors: Wang Xinning , Huang Steve S. , Heston Warren D.W. , Guo Hong , Wang Bing-Cheng , Basilion James P.
Published: April 2023

Supplemental Figure 1:(A) HPLC chromatography of PSMA-1. PSMA-1 has a retention time at 18.6 min. (B) MALDI-TOF mass spectrum of PSMA-1 with M+1=1087.5.
Supplementary Figure S2 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Cisplatin inhibits colony formation of lung squamous cell carcinoma (SCC) cells.
Supplemental Data from Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
Authors: Wang Xinning , Huang Steve S. , Heston Warren D.W. , Guo Hong , Wang Bing-Cheng , Basilion James P.
Published: April 2023

Supplemental Data. This is the procedures associated with the supplemental data
Supplementary Figure S10 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Src phosphorylation does not mediate MAPK/ERK signaling in lung SCC cells.
Supplementary Table 1S and Supplementary Figure 1S from Preclinical Characterization of RSM-932A, a Novel Anticancer Drug Targeting the Human Choline Kinase Alpha, an Enzyme Involved in Increased Lipid Metabolism of Cancer Cells
Authors: Lacal Juan Carlos , Campos Joaquín M.
Published: April 2023

Growth Media for each cell line and structures of compounds used in the study.
Supplemental Figure 2 from Radioprotection of the Brain White Matter by Mn(III) N-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+
Authors: Weitzel Douglas H. , Tovmasyan Artak , Ashcraft Kathleen A. , Rajic Zrinka , Weitner Tin , Liu Chunlei , Li Wei , Buckley Anne F. , Prasad Mark R. , Young Kenneth H. , Rodriguiz Ramona M. , Wetsel William C. , Peters Katherine B. , Spasojevic Ivan , Herndon James E. , Batinic-Haberle Ines , Dewhirst Mark W.
Published: April 2023

Supplemental Figure 2: Neurocognitive analysis of mice by Morris watermaze (A and B), novel object test (C and D), and fear conditioning (E and F). Tests were performed as described (29). (G and H) Distance and velocity during the novel object training and test periods and overall averages.
Supplemental Figure 1 from Radioprotection of the Brain White Matter by Mn(III) N-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+
Authors: Weitzel Douglas H. , Tovmasyan Artak , Ashcraft Kathleen A. , Rajic Zrinka , Weitner Tin , Liu Chunlei , Li Wei , Buckley Anne F. , Prasad Mark R. , Young Kenneth H. , Rodriguiz Ramona M. , Wetsel William C. , Peters Katherine B. , Spasojevic Ivan , Herndon James E. , Batinic-Haberle Ines , Dewhirst Mark W.
Published: April 2023

Supplemental Figure 1: Western analysis of myelin within the corpus callosum. Signal intensity of myelin and actin were quantitated by Image J, averaged within groups, then normalized to the saline group .
Supplementary Table S1 from RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell Carcinoma
Authors: Hazar-Rethinam Mehlika , de Long Lilia Merida , Gannon Orla M. , Boros Samuel , Vargas Ana Cristina , Dzienis Marcin , Mukhopadhyay Pamela , Saenz-Ponce Natalia , Dantzic Daniel D.E. , Simpson Fiona , Saunders Nicholas A.
Published: April 2023

Supplementary Table S1: Differentially expressed genes (List A and List B combined) identified as E2F7-dependent cytotoxic sensitivity genes
Supplementary Table 1 from USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry
Authors: Liu Tieju , Sun Baocun , Zhao Xiulan , Li Yanlei , Zhao Xueming , Liu Ying , Yao Zhi , Gu Qiang , Dong Xueyi , Shao Bing , Lin Xian , Liu Fang , An Jindan
Published: April 2023

Supplementary Table 1. Multivariate analysis of independent prognostic factors in breast cancer patients.
Data Supplement from Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma
Authors: Balbous Anaïs , Renoux Brigitte , Cortes Ulrich , Milin Serge , Guilloteau Karline , Legigan Thibaut , Rivet Pierre , Boissonnade Odile , Martin Sébastien , Tripiana Caroline , Wager Michel , Bensadoun René Jean , Papot Sébastien , Karayan-Tapon Lucie
Published: April 2023

Supplementary Table 1 : Background data on patients 2,3,6 and 12 and analysis of glioblastoma-derived GICs.
Supplementary Figure legends from USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry
Authors: Liu Tieju , Sun Baocun , Zhao Xiulan , Li Yanlei , Zhao Xueming , Liu Ying , Yao Zhi , Gu Qiang , Dong Xueyi , Shao Bing , Lin Xian , Liu Fang , An Jindan
Published: April 2023

Supplementary Figure legends. Figure legends for Supplementary Figure 1-3.
Data Supplement from Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma
Authors: Balbous Anaïs , Renoux Brigitte , Cortes Ulrich , Milin Serge , Guilloteau Karline , Legigan Thibaut , Rivet Pierre , Boissonnade Odile , Martin Sébastien , Tripiana Caroline , Wager Michel , Bensadoun René Jean , Papot Sébastien , Karayan-Tapon Lucie
Published: April 2023

Supplementary Figure 1: Structure of CGP-2 prodrug.
Supplementary Materials and Methods, Figure Legends 1-5 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Authors: Yang Bin-Xia , Duan Yong-Juan , Dong Cheng-Ya , Zhang Fang , Gao Wei-Feng , Cui Xue-Ying , Lin Yong-Min , Ma Xiao-Tong
Published: April 2023

Supplementary Materials and Methods, Figure Legends 1-5 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Supplemental Figure 6 from ΔNP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
Authors: DeCastro Andrew J. , Cherukuri Pratima , Balboni Amanda , DiRenzo James
Published: April 2023

Supplemental Figure 6: Î”NP63Î± does not modulate Epithelial-to-mesenchymal transition in MDA-MB-231 cells. MDA-MB-231 cells were infected with an empty adenoviral control or one encoding Î”NP63Î±. Cells were then collected for qRT-PCR and protein immunoblot analysis 24, 48 and 72 hours post infection. A) qRT-PCR analysis of lysates to detect the relative mRNA expression of the EMT associated genes Snail, Slug, E-Cadherin and Vimentin. B) immunoblot of protein lysates using anti-vimentin, anti-slug, anti-claudin-1 and Î²-actin antibodies. Experiments were performed in triplicate (n = 3), values are mean {plus minus} S.D.
Supplemental Figure 5 from ΔNP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
Authors: DeCastro Andrew J. , Cherukuri Pratima , Balboni Amanda , DiRenzo James
Published: April 2023

Supplemental Figure 5: SDF-1 protein expression in FBS. Western immunoblot against stromal derived factor 1 (SDF1) of protein lysates harvested from fetal bovine serum, DMEM supplemented with 10% FBS and DMEM media without FBS.
Supplementary Figure 3 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Authors: Yang Bin-Xia , Duan Yong-Juan , Dong Cheng-Ya , Zhang Fang , Gao Wei-Feng , Cui Xue-Ying , Lin Yong-Min , Ma Xiao-Tong
Published: April 2023

Supplementary Figure 3 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Supplemental Figure 3 from ΔNP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
Authors: DeCastro Andrew J. , Cherukuri Pratima , Balboni Amanda , DiRenzo James
Published: April 2023

Supplemental Figure 3: MiR203 negatively regulates the expression of CXCR4 mRNA. A) SUM102 cells were transfected with a microRNA control (miR-CON) or mature miR203 at 60 nM final concentration. 48 hours post transfection cells were collected for qRT-PCR analysis to detect the mRNA expression of CXCR4 and CSF2.
Supplementary Figure 2 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Authors: Yang Bin-Xia , Duan Yong-Juan , Dong Cheng-Ya , Zhang Fang , Gao Wei-Feng , Cui Xue-Ying , Lin Yong-Min , Ma Xiao-Tong
Published: April 2023

Supplementary Figure 2 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Supplemental Figure 2 from ΔNP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
Authors: DeCastro Andrew J. , Cherukuri Pratima , Balboni Amanda , DiRenzo James
Published: April 2023

Supplemental Figure 2: Î”NP63Î± adenoviral overexpression and siRNA knockdown experiments in mammary and breast cancer cell lines. A) Immunoblot to detect endogenous expression of Î”NP63Î± in the three cell lines used in this study; IMECs, SUM-102 and MDA-MB-231. B) qRT-PCR analysis to detect the expression of CXCR4 mRNA in IMECs, MCF-7 and MDA-MB-231 cells that were infected with a control adenovirus (Adv-Ctrl) or one expressing Î”NP63Î± (Adv-P63) (Left); Western blot to detect the protein expression of Î”NP63Î± from the same set of experiments (right). C) SUM-102 cells infected with an empty adenovirus or one encoding Î”NP63Î± were fixed and immunoflourescent analysis was performed to detect the expression of CXCR4 protein 24 hours post infection. 40x magnification. D) qRT-PCR analysis of IMECs transfected with siRNA-Scr control (siR-Scr) or siRNA against Î”NP63Î± (siR-P63) to detect the mRNA expression levels of CXCR4 and Î”NP63Î±.
Supplemental Figure 1 from ΔNP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
Authors: DeCastro Andrew J. , Cherukuri Pratima , Balboni Amanda , DiRenzo James
Published: April 2023

Supplemental Figure 1: Expression of validated Î”NP63Î± gene targets in response to Adenoviral Î”NP63Î± overexpression and siRNA-directed knockdown in SUM102 cells. QRT-PCR analysis to detect the relative expression levels of validated Î”NP63Î± target genes (IL-6, IL-8 and CSF2) in SUM102 cells overexpressing Î”NP63Î± (A), and SUM102 cells depleted of Î”NP63Î± via siRNA (20nM) (B).
Data Supplement from BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Authors: Fiskus Warren , Sharma Sunil , Qi Jun , Shah Bhavin , Devaraj Santhana G.T. , Leveque Christopher , Portier Bryce P. , Iyer Swaminathan , Bradner James E. , Bhalla Kapil N.
Published: April 2023

Supplemental Figure 1: Chemical structures the agents utilized in the study. Supplemental Table 1: Clinical presentation and mutational status of the primary AML samples. Supplemental Figure 2: BET protein antagonist and FLT3-TKI induces apoptosis of AML cells. Supplemental Figure 3: BET protein antagonist is synergistic with FLT3-TK inhibitors. Supplemental Figure 4: I-BET151 and FLT3-TKI is synergistic in FLT3-ITD expressing AML. Supplemental Figure 5: JQ1 and ponatinib or AC220 is synergistic against primary AML cells. Supplemental Figure 6: JQ1 and FLT3-TKI does not deplete FLT3 phosphorylation. Supplemental Table 2: Comparison of MOLM13 and MOLM13-TKIR response to anti-leukemia agents. Supplemental Figure 7: Effects of JQ1 and FLT3-TKI treatment in MOLM13-TKIR cells. Supplemental Figure 8: Knockdown of BRD4 enhances sensitivity to JQ1 in MOLM13-TKIR cells. Supplemental Figure 9: JQ1 and panobinostat is synergistic against MV4-11 TKIR cells.
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Supplementary Materials and Methods
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Figure S1: Anti-lymphatic compounds do not disrupt the blood vasculature. Figure S2: Simvastatin and lovastatin inhibit blood and lymphatic vessel development. Figure S3: Flunarizine causes apoptosis in parachordal lymphangioblasts. Figure S4: Bodyweight changes in mice treated with anti-lymphatic compounds. Figure S5: Bioluminescent imaging of primary tumour growth. Supplementary Table 1. VEGFR IC50 values for lymphatic inhibitors.
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Video S3. Confocal time-lapse imaging of a lyve1:egfp embryo from 30 hpf to 49:42 hpf (19:42h) treated with 4 μM leflunomide. Time-lapse image z-stacks were collected 10 min apart; movie was made at 7 frames per second.
Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Authors: Hamblett Kevin J. , Kozlosky Carl J. , Siu Sophia , Chang Wesley S. , Liu Hua , Foltz Ian N. , Trueblood Esther S. , Meininger David , Arora Taruna , Twomey Brian , Vonderfecht Steven L. , Chen Qing , Hill John S. , Fanslow William C.
Published: April 2023

Supplementary Figure S1. Regression of U251vIII Human GBM Subcutaneous Xenografts Following AMG 595 Treatment
Supplementary Figure Legends and Supplementary Table. from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Authors: Hamblett Kevin J. , Kozlosky Carl J. , Siu Sophia , Chang Wesley S. , Liu Hua , Foltz Ian N. , Trueblood Esther S. , Meininger David , Arora Taruna , Twomey Brian , Vonderfecht Steven L. , Chen Qing , Hill John S. , Fanslow William C.
Published: April 2023

Supplementary Figure Legends and Supplementary Table. Supplementary Table. EGFRvIII receptors/cell quantification of U251vIII and D317
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Video S5. Confocal time-lapse imaging of a lyve1:egfp;kdrl:nls:mcherry embryo from 48 hpf to 68.02 hpf (20:02h) treated with 1 % DMSO. Left panel is the lyve1:egfp channel (green), middle panel is the kdrl:nls:mcherry channel (red) and the right panel is the merged image. Numbers in the kdrl:nls:mcherry and the merged channel represent tracked lymphangioblasts (Figure 4). Time-lapse image z-stacks were collected 10 min apart; movie was made at 7 frames per second.
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Video S6. Confocal time-lapse imaging of a lyve1:egfp;kdrl:nls:mcherry embryo from 48 hpf to 68.02 hpf (20:02h) treated with 5 μM flunarizine. Left panel is the lyve1:egfp channel (green), middle panel is the kdrl:nls:mcherry channel (red) and the right panel is the merged image. Numbers in the kdrl:nls:mcherry and the merged channel represent tracked lymphangioblasts (Figure 4). Time-lapse image z-stacks were collected 10 min apart; movie was made at 7 frames per second.
Supplementary Table 1 from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Authors: Paulitschke Verena , Berger Walter , Paulitschke Philipp , Hofstätter Elisabeth , Knapp Bernhard , Dingelmaier-Hovorka Ruth , Födinger Dagmar , Jäger Walter , Szekeres Thomas , Meshcheryakova Anastasia , Bileck Andrea , Pirker Christine , Pehamberger Hubert , Gerner Christopher , Kunstfeld Rainer
Published: April 2023

Activity of vemurafenib and M8 against A375, M24met and V0, V0.1, V1, V10 (Proliferation assay).*Paulitschke et al. 2010
Supplementary Figure 3 from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Authors: Paulitschke Verena , Berger Walter , Paulitschke Philipp , Hofstätter Elisabeth , Knapp Bernhard , Dingelmaier-Hovorka Ruth , Födinger Dagmar , Jäger Walter , Szekeres Thomas , Meshcheryakova Anastasia , Bileck Andrea , Pirker Christine , Pehamberger Hubert , Gerner Christopher , Kunstfeld Rainer
Published: April 2023

Inflammatory profile in A375 and M24met melanoma cells. Distribution of inflammatory proteins in A375 and M24met (a). M8 downregulates proteins involved in inflammation, as exemplified by the inflammatory proteins lysyl oxidase homolog 2, plasminogen activator inhibitor 1 (PAI-1), ADAMTS-1, pentraxin, granulins, that are upregulated in M24met (b,c). Correlation of the candidates with tumor microenvironment and IL-1beta and VEGF response (d).
Supplementary Figure 1 from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Authors: Paulitschke Verena , Berger Walter , Paulitschke Philipp , Hofstätter Elisabeth , Knapp Bernhard , Dingelmaier-Hovorka Ruth , Födinger Dagmar , Jäger Walter , Szekeres Thomas , Meshcheryakova Anastasia , Bileck Andrea , Pirker Christine , Pehamberger Hubert , Gerner Christopher , Kunstfeld Rainer
Published: April 2023

Morphologic characterization of A375 and M24met melanoma cells. (a) Microscopic analyses; the arrows indicate a round cell of A375 and a tube-like structure formed by M24met. Immunohistochemical staining of A375 (b) and M24met (c) with S100, HMB45, Nestin, and p75NTR. (d) FACS analysis of A375, M24met and solvent control with CD90, FE, CD45, CD31, CD34 and CD40.
Supplementary Figure 2 from Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo
Authors: Xia Yun , Cai Xian-Yi , Fan Ji-Quan , Zhang Li-Ling , Ren Jing-Hua , Chen Jing , Li Zhen-Yu , Zhang Rui-Guang , Zhu Fang , Wu Gang
Published: April 2023

(A) HE staining of tissue section. A vessel formed with elongated endothelial cells was showed by a red arrow, moreover, the vessel lack of endothelial cells nearby was pointed out by a yellow arrow. Original magnification, Ã—400. (B) Plenty of blood sinusoids were observed in the CD31/PAS dual-stained sections. Original magnification, Ã—100. (C) Endothelial cell lined-blood vessels containing CD31-positive immunoreactivity (dark brown) . (D) A VM structure were strictly defined as PAS-positive (purple magenta) CD31-negative. Detached tumor cells (black arrows) reached the blood stream, and it is suggested that VM networks facilitate tumor metastasis. Original magnification, Ã—400.
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Figure 2. H&E images of tumors and normal organs from orthotopic xenograft assay with ICG-001.
Supplementary Figure 6 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file shows IHC slides of H526 tumors taken from mice treated with or without AZD3965 and stained for MCT4 or CD31 expression.
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Figure 4. Gene ontology terms enriched in gene expression microarray analysis following ICG-001 treatment.
Supplementary Figure 4 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file shows that Inhibition of lactate transport by AZD3965 can cause oxidative stress.
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Table 2. Summary of tumor spread and clinical manifestations in orthotopic xenograft model.
Supplementary Figure 2 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file shows a hierarchical analysis of individual metabolites
Supplementary Figure 1 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file shows thes tructure of AZD3965, which is the S enantiomer.
Supplementary Table S3 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Authors: Ohkubo Shuichi , Kodama Yasuo , Muraoka Hiromi , Hitotsumachi Hiroko , Yoshimura Chihoko , Kitade Makoto , Hashimoto Akihiro , Ito Kenjiro , Gomori Akira , Takahashi Koichi , Shibata Yoshihiro , Kanoh Akira , Yonekura Kazuhiko
Published: April 2023

Supplementary Table S3: Retinal and tumoral distributions of HSP90 inhibitors in an NCI-H1975 rat xenograft model.
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
Authors: Custodio Ana , Moreno-Rubio Juan , Aparicio Jorge , Gallego-Plazas Javier , Yaya Ricardo , Maurel Joan , Rodríguez-Salas Nuria , Burgos Emilio , Ramos David , Calatrava Ana , Andrada Encarna , Díaz-López Esther , Sánchez Antonio , Madero Rosario , Cejas Paloma , Feliu Jaime
Published: April 2023

Supplementary Table S1. Genotype proportions for SELE rs3917413 and MTHFR rs1801133 SNP in the training and validation cohorts.
Supplementary Table S1 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Authors: Ohkubo Shuichi , Kodama Yasuo , Muraoka Hiromi , Hitotsumachi Hiroko , Yoshimura Chihoko , Kitade Makoto , Hashimoto Akihiro , Ito Kenjiro , Gomori Akira , Takahashi Koichi , Shibata Yoshihiro , Kanoh Akira , Yonekura Kazuhiko
Published: April 2023

Supplementary Table S1: Inhibitory activity of TAS-116 and staurosporine against a panel of 48 protein kinases.
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
Authors: Custodio Ana , Moreno-Rubio Juan , Aparicio Jorge , Gallego-Plazas Javier , Yaya Ricardo , Maurel Joan , Rodríguez-Salas Nuria , Burgos Emilio , Ramos David , Calatrava Ana , Andrada Encarna , Díaz-López Esther , Sánchez Antonio , Madero Rosario , Cejas Paloma , Feliu Jaime
Published: April 2023

Supplementary Table S3. Cox regression multivariate analysis for disease free survival (DFS) in stage III colon cancer patients.
Supplementary Table S3 from A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels MAGEA3/6 as a Marker for Recurrence
Authors: Zamunér Fernando Tadeu , Karia Bruno Takao Real , de Oliveira Cleyton Zanardo , Santos Carlos Roberto dos , Carvalho André Lopes , Vettore André Luiz
Published: April 2023

Supplementary Table S3: Correlation between CTA expression and clinical and pathological features of HNSCC patients.
Supplementary Table S2 from A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels MAGEA3/6 as a Marker for Recurrence
Authors: Zamunér Fernando Tadeu , Karia Bruno Takao Real , de Oliveira Cleyton Zanardo , Santos Carlos Roberto dos , Carvalho André Lopes , Vettore André Luiz
Published: April 2023

Supplementary Table S2: Main characteristics of the 36 CTAs profiled in the study according to CTDatabase (http://www.cta.lncc.br/).
Supplementary Tables 1-3 and Figure 1-7 from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Authors: Hancox Urs , Cosulich Sabina , Hanson Lyndsey , Trigwell Cath , Lenaghan Carol , Ellston Rebecca , Dry Hannah , Crafter Claire , Barlaam Bernard , Fitzek Martina , Smith Paul D. , Ogilvie Donald , D'Cruz Celina , Castriotta Lillian , Wedge Stephen R. , Ward Lara , Powell Steve , Lawson Mandy , Davies Barry R. , Harrington Elizabeth A. , Foster Emily , Cumberbatch Marie , Green Stephen , Barry Simon T.
Published: April 2023

Supplementary Tables 1-3 and Figure 1-7. Supp Table 1 Summary of cell line origins and verification. Supp Table 2 Summary of antibodies used in all experimental analysis Supp Fig 1 AZD8186 inhibits PI3K pathway in PTEN null but not PTEN WT PIKC3A MT cells Supp Fig 2 AZD8186 inhibits LPA, EGF and rac dependent Ser473 AKT phosphorylation in serum starved prostate and breast cancer cells Supp Fig 3 Western blot analysis of showing induction of FOXO3a association with the chromatin fraction following treatment with AZD8186 Supp Fig 4 AZD8186 inhibits proliferation in a subset of cancer cell lines Supp Table 3 GI50 of all cell lines showing sensitivity to AZD8186 Supp Fig 5 Western blot protein analysis of PTEN status across a panel of breast and prostate cell lines Supp Fig 6 Pathway biomarker suppression in PC3 and HID28 tumours Supp Fig 7 AZD8186 selectively suppresses pathway biomarkers in tumour versus lung
Supplementary Table S1 from A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels MAGEA3/6 as a Marker for Recurrence
Authors: Zamunér Fernando Tadeu , Karia Bruno Takao Real , de Oliveira Cleyton Zanardo , Santos Carlos Roberto dos , Carvalho André Lopes , Vettore André Luiz
Published: April 2023

Supplementary Table S1: Sequences of primers used in this study and PCR conditions.
Supplementary Figure 6-10 from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells
Authors: Chen Bryan Wei , Chen Wei , Liang Hui , Liu Hao , Liang Chao , Zhi Xiao , Hu Li-qiang , Yu Xia-Zhen , Wei Tao , Ma Tao , Xue Fei , Zheng Lei , Zhao Bin , Feng Xin-Hua , Bai Xue-li , Liang Ting-bo
Published: April 2023

Supplemental Figure 6. Knockdown of AKT promotes G0/G1 arrest and downregulates MDR1; Supplemental Figure 7. Activation of mTOR in HCC samples; Supplemental Figure 8. AKT inhibition promotes G0/G1 arrest; Supplemental Figure 9. Knockdown of AKT downregulates MDR1 mRNA expression; Supplemental Figure 10. Diagram showing the role of mTORC2 in HCC.
Supplementary Figure 1-5 from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells
Authors: Chen Bryan Wei , Chen Wei , Liang Hui , Liu Hao , Liang Chao , Zhi Xiao , Hu Li-qiang , Yu Xia-Zhen , Wei Tao , Ma Tao , Xue Fei , Zheng Lei , Zhao Bin , Feng Xin-Hua , Bai Xue-li , Liang Ting-bo
Published: April 2023

Supplemental Figure 1. Effect of rapamycin and OSI-027 on HCC cell proliferation; Supplemental Figure 2. Effect of OSI-027 on apoptosis in HCC cells; Supplemental Figure 3. Effect of rapamycin and OSI-027 on HCC cell cycle progression; Supplemental Figure 4. Knockdown of Rictor or mTOR, but not Raptor, results in cell cycle arrest; Supplemental Figure 5. Knockdown of MDR1 diminishes the synergistic effect of OSI-027 and doxorubicin.
Supplementary Table S1 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Table S1. List SL1. Candidates meeting synthetic lethal criteria of <50% death in MCF10A and {greater than or equal to}15% increased death in CDH1-/- cells compared to MCF10A cells.
Supplementary Figure S4 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Figure S4. Additional HDAC inhibitor assays.
Supplementary Figure S3 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Figure S3. Alternative real time assays.
Figure S1 from Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
Authors: Li Nan , Maly Dustin J. , Chanthery Yvan H. , Sirkis Daniel W. , Nakamura Jean L. , Berger Mitchel S. , James C. David , Shokat Kevan M. , Weiss William A. , Persson Anders I.
Published: April 2023

Figure S1. A chemical screen of multi-targeted kinase inhibitors identify compounds that induce apoptosis in human glioblastoma cultures.
Supplementary Figure legends from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 6 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Figure 6. Expression levels of U2AF65 and ASF/SF2 in human clinical PCa samples
Supplementary Figure 5 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Figure 5. qPCR analysis of AR variant levels in PCa cells after donwregulation of c-Myc expression
Supplementary Figure 4 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Figure 4. Expression levels of hnRNPA2 in human clinical PCa samples
Supplementary Figure 2 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Figure 2. qPCR analysis of AR variant levels in PCa cells after down- or up-regulation of hnRNPA1
Supplementary Methods from Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments
Authors: Li Keyu , Tavaré Richard , Zettlitz Kirstin A. , Mumenthaler Shannon M. , Mallick Parag , Zhou Yu , Marks James D. , Wu Anna M.
Published: April 2023

Supplementary methods not included in the primary manuscript.
Supplementary Figures S1-S5 from Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer
Authors: Kodama Tatsushi , Tsukaguchi Toshiyuki , Satoh Yasuko , Yoshida Miyuki , Watanabe Yoshiaki , Kondoh Osamu , Sakamoto Hiroshi
Published: April 2023

Supplementary Figures S1-S5. Figure S1: Kinase selectivity of alectinib, vandetanib, cabozantinib, sorafenib, sunitinib, and ponatinib against several kinases including RET. Figure S2: Effect of crizotinib or LDK378 against Ba/F3 cells expressing KIF5B-RET. Figure S3: Effects of alectinib on the expression levels of phospho-ERK, ERK, and BIM in Ba/F3 cells expressing KIF5B-RET. Figure S4: Structures of RET, RET V804L, and V804M with alectinib and vandetanib. Figure S5: X-ray structure of crizotinib with ROS1 and 3D models of alectinib and LDK378 on ROS1.
Supplemental Figure 3 from CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis
Authors: Burgos-Ojeda Daniela , Wu Rong , McLean Karen , Chen Yu-Chih , Talpaz Moshe , Yoon Euisik , Cho Kathleen R. , Buckanovich Ronald J.
Published: April 2023

Supplemental Figure 3. Stem cell gene expression in CD24+ and CD24- cells and CD44+ and CD44- cells
Supplemental Figure 2 from CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis
Authors: Burgos-Ojeda Daniela , Wu Rong , McLean Karen , Chen Yu-Chih , Talpaz Moshe , Yoon Euisik , Cho Kathleen R. , Buckanovich Ronald J.
Published: April 2023

Supplemental Figure 2. FACS analysis of CD24 and CD133 expression of CD24+ or CD24- tumors
Supplementary Figure S4 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Authors: Ramirez Yulian P. , Mladek Ann C. , Phillips Roger M. , Gynther Mikko , Rautio Jarkko , Ross Alonzo H. , Wheelhouse Richard T. , Sakaria Jann N.
Published: April 2023

Supplementary Figure S4. DP86 and DP68 activity is independent of MMR expression. (A) Western blot confirmed knockdown in T98G cells infected with empty vector, sheGFP, and two shRNAs targeting MLH1. (B) Infected cells were treated with TMZ, DP86, or DP68 and cell survival was analyzed via CyQuant assay. Mean IC50 {plus minus} SEM from three independent experiments are graphed. * (p<0.05)
Supplementary Materials and Methods from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
Authors: Proia Theresa , Jiang Feng , Bell Alisa , Nicoletti Richard , Kong Lingxin , Kreuter Kelly , Poling Laura , Winston William M. , Flaherty Meghan , Weiler Solly , Perino Samantha , O'Hagan Ronan , Lin Jie , Gyuris Jeno , Okamura Heidi
Published: April 2023

Supplementary Materials and Methods. Description of Materials and Methods for experiments in supplementary data.
Supplementary Figure S1 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Authors: Ramirez Yulian P. , Mladek Ann C. , Phillips Roger M. , Gynther Mikko , Rautio Jarkko , Ross Alonzo H. , Wheelhouse Richard T. , Sakaria Jann N.
Published: April 2023

Supplementary Figure S1. Structures of TMZ, DP68, and DP86.
Supplementary Figure Legends from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Authors: Ramirez Yulian P. , Mladek Ann C. , Phillips Roger M. , Gynther Mikko , Rautio Jarkko , Ross Alonzo H. , Wheelhouse Richard T. , Sakaria Jann N.
Published: April 2023

Legends for Supplementary Figures S1-S5.
Supplementary Figure S1 from Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer
Authors: Patterson Andrea M. , Kaabinejadian Saghar , McMurtrey Curtis P. , Bardet Wilfried , Jackson Ken W. , Zuna Rosemary E. , Husain Sanam , Adams Gregory P. , MacDonald Glen , Dillon Rachelle L. , Ames Harold , Buchli Rico , Hawkins Oriana E. , Weidanz Jon A. , Hildebrand William H.
Published: April 2023

RL21A is specific for the HLA-A2/MIF19-27 complex.
Supplementary Figure 1 from Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
Authors: Martinez-Font Esther , Felipe-Abrio Irene , Calabuig-Fariñas Silvia , Ramos Rafael , Terrasa Josefa , Vögler Oliver , Alemany Regina , Martín-Broto Javier , Obrador-Hevia Antònia
Published: April 2023

Supplementary Figure 1. Real time cell growth monitorization of STS cells upon treatment with PKF118-310
Supplementary Figures 1 through 3 from Pigment Epithelium–Derived Factor Alleviates Tamoxifen-Induced Endometrial Hyperplasia
Authors: Goldberg Keren , Bar-Joseph Hadas , Grossman Hadas , Hasky Noa , Uri-Belapolsky Shiri , Stemmer Salomon M. , Chuderland Dana , Shalgi Ruth , Ben-Aharon Irit
Published: April 2023

Figure 1: schematic representation of experimental design Figure 2: Histological manifestation of treated uteri at the short-term setting Figure 3: uterine characteristics following "rPEDF prevention" regimen
Supplementary Information from Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Authors: Huang Qingling , Schneeberger Valentina E. , Luetteke Noreen , Jin Chengliu , Afzal Roha , Budzevich Mikalai M. , Makanji Rikesh J. , Martinez Gary V. , Shen Tao , Zhao Lichao , Fung Kar-Ming , Haura Eric B. , Coppola Domenico , Wu Jie
Published: April 2023

Supplementary Methods, radiologist's reading of CT images, supplementary figure legends, supplementary references
Supplementary Tables S1-S7 and Supplementary Figure Legends from Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Authors: Jiang Wei , Liu Na , Chen Xiao-Zhong , Sun Ying , Li Bin , Ren Xian-Yue , Qin Wei-Feng , Jiang Ning , Xu Ya-Fei , Li Ying-Qin , Ren Jian , Cho William CS , Yun Jing-Ping , Zeng Jing , Liu Li-Zhi , Li Li , Guo Ying , Mai Hai-Qiang , Zeng Mu-Sheng , Kang Tie-Bang , Jia Wei-Hua , Shao Jian-Yong , Ma Jun
Published: April 2023

Supplementary Table S1: Clinicopathological Characteristics of 24 NPC and 24 NCNBT Supplementary Table S2: Clinical Characteristics of Nasopharyngeal Carcinoma Patients According to Gene Methylation Panel in Training, Validation, and Independent Cohorts. Supplementary Table S3: Primer Sequences of 28 Genes and GAPDH Supplementary Table S4: Primer Used for Pyrosequencing Methylation Analysis of Candidate Genes Supplementary Table S6: Data Analysis with PubMeth and NCBI PubMed Supplementary Table S7: Correlation Analysis between Methylation of Six Genes in the Training Cohort
Supplementary figures S1 to S3 from Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling
Authors: Li Jiannong , Fang Bin , Kinose Fumi , Bai Yun , Kim Jae-Young , Chen Yian A. , Rix Uwe , Koomen John M. , Haura Eric B.
Published: April 2023

Figure S1. Compounds screen across SCLC cell lines Figure S2. Aurora kinase B identified by drug profiling in H82 cells and drive cell survival in MYC amplified SCLC Figure S3. TBK1 identified by drug profiling in SW210.5 cells
Supplementary Figure S1: Representative Pyrograms of Methylation Analysis by Bisulfite Pyrosequencing. from Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Authors: Jiang Wei , Liu Na , Chen Xiao-Zhong , Sun Ying , Li Bin , Ren Xian-Yue , Qin Wei-Feng , Jiang Ning , Xu Ya-Fei , Li Ying-Qin , Ren Jian , Cho William CS , Yun Jing-Ping , Zeng Jing , Liu Li-Zhi , Li Li , Guo Ying , Mai Hai-Qiang , Zeng Mu-Sheng , Kang Tie-Bang , Jia Wei-Hua , Shao Jian-Yong , Ma Jun
Published: April 2023

Representative Pyrograms of Methylation Analysis by Bisulfite Pyrosequencing.
Supplementary Table S2 from Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling
Authors: Li Jiannong , Fang Bin , Kinose Fumi , Bai Yun , Kim Jae-Young , Chen Yian A. , Rix Uwe , Koomen John M. , Haura Eric B.
Published: April 2023

Hits of E08 and N09 identified by ATP probe-based drug profiling in H82 cells
Supplemental Figures 1-2 from Alterative Expression and Localization of Profilin 1/VASPpS157 and Cofilin 1/VASPpS239 Regulates Metastatic Growth and Is Modified by DHA Supplementation
Authors: Ali Mehboob , Heyob Kathryn , Jacob Naduparambil K. , Rogers Lynette K.
Published: April 2023

Supplemental Figure 1. Histograms for Flow Cytometry Analysis. Supplemental Figure 2. DHA alters ABPs subcellular distribution.
Supplementary Table S1. from Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling
Authors: Li Jiannong , Fang Bin , Kinose Fumi , Bai Yun , Kim Jae-Young , Chen Yian A. , Rix Uwe , Koomen John M. , Haura Eric B.
Published: April 2023

Cell viability screen in SCLC cells against Roche published kinase inhibitor set
Supplementary Figures from Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate–Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma
Authors: Liu Chia-Wen , Hua Kuo-Tai , Li Kai-Chun , Kao Hsiang-Fong , Hong Ruey-Long , Ko Jenq-Yuh , Hsiao Michael , Kuo Min-Liang , Tan Ching-Ting
Published: April 2023

Supplementary figure 1. Characterization of the cisplatin-resistant HNSCC cell lines. Supplementary figure 2. Genetic or pharmacological inhibition of G9a promotes cisplatin-induced apoptosis in SAS-CR cells.Supplementary figure 3. Depletion of G9a increases the sensitivity to cisplatin in OECM-1 cells.Supplementary figure 4. Depletion of G9a increases the platinum-DNA adduct accumulation. Supplementary figure 5. Inhibition of G9a by shRNA or enzymatic inhibitor decreases intracellular GSH levels. Supplementary figure 6. Multi-drug resistance to chemotherapeutic agents in G9a-overexpressed SAS cells. Supplementary figure 7. Effect of G9a on the expression of GSH synthesis enzymes. Supplementary figure 8. The expression of GSH synthesis enzymes in mouse xenograft tumors. Supplementary figure 9. ATF4 upregulates GCLC in cisplatin-resistant cells. Supplementary figure 10. Upregulated GCLC is required for G9a to promote cisplatin resistance.
Supplementary Methods from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Authors: Kelly Marcus P. , Hickey Carlos , Makonnen Sosina , Coetzee Sandra , Jalal Sumreen , Wang Yu , Delfino Frank , Shan Jing , Potocky Terra B. , Chatterjee Ishita , Andreev Julian , Kunz Arthur , D'Souza Christopher , Giurleo Jason T. , Nittoli Thomas , Trail Pamela A. , Thurston Gavin , Kirshner Jessica R.
Published: April 2023

Additional details of methods covered in the main materials and methods section
Supplementary Figure S1 - S8 from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Authors: Kelly Marcus P. , Hickey Carlos , Makonnen Sosina , Coetzee Sandra , Jalal Sumreen , Wang Yu , Delfino Frank , Shan Jing , Potocky Terra B. , Chatterjee Ishita , Andreev Julian , Kunz Arthur , D'Souza Christopher , Giurleo Jason T. , Nittoli Thomas , Trail Pamela A. , Thurston Gavin , Kirshner Jessica R.
Published: April 2023

Supplementary Figures S1 - S8 as referenced in the main article